For decades, multinational companies came to China for one reason: the market.

That logic is now changing.

French pharmaceutical and dermo-cosmetics group Pierre Fabre Laboratories is expanding its investment in China — not just to sell more, but to build deeper capabilities inside the country.

China is now one of the company’s top global priorities, and a key pillar of its long-term growth strategy.

📊 More than just growth

The company’s China business has been growing steadily:

• Strong momentum in oncology treatments, especially in lung and breast cancer
• Continued expansion of dermo-cosmetics brands like Avène
• E-commerce now accounts for two-thirds of its cosmetics sales in China

But the real story isn’t growth.

👉 It’s transformation.

🧪 A shift toward local innovation

In 2023, the company launched a China Innovation Center — one of only three globally.

This marks a critical shift:

• From importing global products
• To developing products inside China, for Chinese consumers

Some of these locally developed products are now expected to contribute a growing share of sales.

🤝 Deepening local partnerships

The company is also strengthening ties with Chinese players, including a strategic cooperation with Sinopharm.

The goal:

• Combine global R&D
• With China’s distribution, clinical, and regulatory capabilities

At first glance, this looks like a typical multinational expansion story.

It’s not.

👉 It reflects a much bigger shift in how global companies are repositioning themselves inside China.

👉 Continue reading to see why China is no longer just a market — and how multinationals are quietly rebuilding their global strategies around it.

From Market to Engine: How Multinationals Are Rebuilding Inside China

What Pierre Fabre Laboratories is doing in China is part of a broader structural shift.

Multinationals are no longer treating China as an endpoint for sales.

They are turning it into a core part of how they operate globally.

1️⃣ From “selling in China” to “building in China”

The traditional model was simple:

• Develop products in Europe or the US
• Manufacture at scale
• Sell into China

That model is being replaced by something more complex:

👉 Build, test, and refine inside China itself

This includes:

• Local R&D centers
• China-specific product development
• Integration with local clinical data and consumer behavior

2️⃣ China as an innovation laboratory

China offers something few markets can:

• Large, fast-moving consumer base
• Advanced digital platforms
• Rapid feedback cycles

For companies like Pierre Fabre:

👉 China becomes a real-time testing ground

In dermo-cosmetics, for example:

• Sensitive-skin solutions are tailored specifically for Chinese consumers
• E-commerce strategies are refined on platforms like Tmall and Douyin
• Successful models are later exported globally

3️⃣ The rise of “reverse globalization”

One of the most important shifts:

👉 Innovation is no longer flowing only into China —
it is increasingly flowing out of China.

Examples in this case:

• China-developed products entering global pipelines
• E-commerce playbooks being replicated in other markets

This creates a new pattern:

Global strategy is being shaped inside China

4️⃣ Embedded partnerships with local players

Multinationals are no longer operating independently.

They are becoming deeply embedded in China’s ecosystem.

The partnership with Sinopharm reflects this:

• Global innovation meets local execution
• Regulatory navigation becomes localized
• Market access is co-built, not outsourced

👉 This is not outsourcing — it is structural integration

5️⃣ Why China still matters — despite global uncertainty

At a time when geopolitical tensions are rising, this trend may seem counterintuitive.

But for many companies, China still offers:

• Scale
• Infrastructure
• Policy support in strategic sectors like biotech
• A pathway to long-term growth

👉 The result is not decoupling, but reconfiguration

⚠️ What this means going forward

This shift raises important strategic questions:

• Will global companies become more dependent on China-based capabilities?
• Can innovations developed in China be fully globalized?
• How will regulatory and geopolitical risks reshape these strategies?

But one direction is clear:

👉 China is no longer optional in global strategy design.

🧩 Bottom Line

This is not just an investment story.

It is a structural shift in globalization.

China is evolving from a sales market into a core engine of innovation, execution, and growth for multinational companies.

And companies that adapt to this shift early may define the next phase of global competition.